Sumitomo Dainippon Pharma Co Ltd (4506)

481.0 +1.0 (+0.21%)
Closed JPY Disclaimer

Sumitomo Dainippon Pharma Co Ltd Company Profile

Industry
Pharmaceuticals
Sector
Healthcare
Employees
6250
Equity Type
ORD
Sumitomo Pharma Co., Ltd. engages in the manufacture and sale of pharmaceuticals, food ingredients and additives, veterinary medicines, and others in Japan, North America, China, and internationally. The company offers pharmaceutical products, such as therapeutic agents for Parkinson’s disease, uterine fibroids, depression, type 2 diabetes, systemic fungal infection, hypertension, pruritus, advanced prostate cancer, overactive bladder, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It provides products for atypical antipsychotic, cultured thymus tissue for pediatric congenital athymia, antiepileptic, and carbapenem antibiotic; and Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, as well as seasonings, such as soups or bouillons; and chemical product materials, which include pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, such as dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. It has partnerships with Keio University; RIKEN; Kyoto University; and collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company has a strategic alliance with Roivant Sciences Ltd. The company was formerly known as Sumitomo Dainippon Pharma Co., Ltd. and changed its name to Sumitomo Pharma Co., Ltd. in April 2022. The company was incorporated in 1897 and is headquartered in Osaka, Japan. Sumitomo Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.
Contact Information
Address
Osaka,541-0045 Japan
Phone
81 6 6203 5321
Fax
81 6 6202 6028
Top Executives
Name
Age
Since
Title
Hiroshi Nomura 66 2012 CEO, President & Representative Director
Mayumi Mochizuki 69 2021 Outside Audit & Supervisory Board Member
Daishiro Michimori 0 2022 Outside Audit & Supervisory Board Member
Takashi Kutsunai 65 2014 Full-Time Audit & Supervisory Board Member
Hiroyuki Baba 64 2014 Mngg Exec. Officer of Global Data Design, Lgl Affairs. IP, IT Mgt, & Frontier Bus. Off. & Director
Yoshiharu Ikeda 65 2020 Managing Executive Officer of Drug Research Division, Head of Japan Business Unit & Director
Nobuhiro Endo 70 2019 Independent Outside Director
Saeko Arai 59 2018 Independent Outside Director
Toru Kimura 63 2016 Sr. Mngg Exec. Off. of Glo. Crprate Stgy, F&A, Regen & Cell Med. Off., Kobe Ctr, Mfg. Plt and Dir.
Shigeyuki Nishinaka 59 2014 Managing Executive Officer of Business Development & Management and Director
Minoru Usui 68 2021 Independent Outside Director
Koji Fujimoto 60 2022 Independent Outside Director
Yoshio Iteya 67 2018 Outside Audit & Supervisory Board Member
Hisayoshi Kashima 0 2014 Full-Time Audit & Supervisory Board Member
Clear All
0Selected
Please try another search

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.